In addition, in the negative cases analysis of the additional cancer-related genes should be considered, including MMR genes, BRIP1, RAD51C, and RAD51D. Unfortunately, given the potential costs of such expanded diagnostics, it will probably need to be limited to the selected group of patients with specific clinical and histopathological characterization. This evidence concerns the gene RAD51D and cancer.